*/
Lev Gerlovin, Ezra Josephson | Life Sciences
Let’s say interchangeability is a viable regulatory option for manufacturers of biosimilars. Would it always make sense to seek an interchangeability designation from a strategic perspective? Because of the diversity and complexity of product and manufacturer characteristics, there may not be a single optimal strategy, but rather a continuum. Click below to read the article.
Analytics for clinical development strategy: Tools and opportunities
In the final part of the series, CRA’s Dr. Nick Davies presents an overview of current and emerging analytical tools and explores the opportunities for their...